COLUMVI (glofitamab-gxbm) injection

Columvi is a cancer medicine used to treat adults with a blood cancer called diffuse large B-cell lymphoma (DLBCL) whose cancer has returned (relapsed) or stopped responding (refractory) after at least two previous treatments.

Home | rezafungin for injection

REZZAYO (rezafungin for injection) Price In India Ahmedabad Bengaluru Chennai Kolkata Mumbai
COLUMVI (glofitamab-gxbm) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

COLUMVI (glofitamab-gxbm) injection

Glofitamab-gxbm is approved to treat: B-cell non-Hodgkin lymphoma (NHL) that has come back or did not get better after at least two other systemic therapies. It is used in adults with the following types of B-cell NHL: Diffuse large B-cell lymphoma (DLBCL).

The Food and Drug Administration (FDA) has granted accelerated approval to Columvi® (glofitamab-gxbm) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after 2 or more lines of systemic therapy.

Glofitamab, sold under the brand name Columvi, is a bispecific monoclonal antibody used for the treatment of large B-cell lymphoma.[10] It is a bispecific CD20-directed CD3 T-cell engager.

It was approved for medical use in Canada in July 2023, in the United States in June 2023, and in the European Union in July 2023.

Glofitamab is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Specifically it is indicated for the treatment of adults with certain types of diffuse large B-cell lymphoma or large B-cell lymphoma who have received at least two prior treatments that did not work or are no longer working.

Drug (Brand / Generic): COLUMVI /glofitamab-gxbm
Current Indication: treat large B-cell lymphoma
Approval Date: 2023

 2.5 mg/2.5 mL (1 mg/mL) in a single-dose vial. 
 10 mg/10 mL (1 mg/mL) in a single-dose vial. 

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.